Submitted:
12 September 2026
Posted:
18 September 2026
You are already at the latest version
Abstract
Background: Radical cystectomy (RC) with urinary diversion is considered the standard treatment for muscle-invasive and selected cases of high-risk non-muscle invasive bladder cancer. As a complex procedure it carries a high risk for complications, especially infectious ones. Orthotopic ileal neobladders (IN) have the highest risk of infectious complications and hospital readmission in comparison to ileal conduits. Unfortunately, the evidence for antibiotic management, including periprocedural prophylaxis and treatment of asymptomatic bacteriuria (ASB) in this special patient cohort is still limited. Furthermore, there is no international consensus on the clinical risk factors that justify intensified antibiotic use, leading to wide practice variability and concerns regarding antimicrobial stewardship. Objective: This Delphi consensus study aims to identify the best antibiotic management, including periprocedural prophylaxis as well as treatment of ASB, and define procedural, patient-related and microbiological risk factors that warrant antibiotic intensified usage in patients with RC and IN and to establish evidence-informed best practice recommendations. Methods: A modified three-round Delphi process will be conducted in accordance with DELPHISTAR guideline. A diverse panel of 30 – 40 international experts in urology, infectious diseases, microbiology, antimicrobial stewardship and medical oncologists will anonymously give recommendations for antibiotic management and evaluate predefined and newly suggested risk factors using a 6-point Likert scale. Consensus will be defined as ≥70% of participants rating an item as highly important (score 5–6) and <15% rating it as unimportant (score 1–2). Items failing to reach consensus in Rounds 1 and 2 will be reevaluated in subsequent rounds. Outcomes: The primary outcomes are consensus-based best practice recommendation for periprocedural antibiotic prophylaxis, antibiotic prophylaxis for catheter removal and definition of ASB as well as antibiotic management of ASB. The secondary outcome will be a consensus-based list of risk factors justifying intensified antibiotic usage in patients with RC and IN. Dissemination: Findings will be submitted for publication in peer-reviewed journals to support global efforts in harmonizing practice and promoting responsible antibiotic use in bladder cancer treatment with RC and IN.
Keywords:
bladder cancer
; radical cystectomy
; ileal neobladder
; antibiotics
; antimicrobial stewardship
; asymptomatic bacteriuria
Background
Radical cystectomy (RC) with urinary diversion is considered the standard treatment for muscle-invasive and selected cases of high-risk non-muscle invasive bladder cancer (BC) [1,2]. As one of the technically most complex urological surgeries, RC carries a considerable perioperative risk as well as a risk for post-operative complications, especially infectious complications [3,4,5]. Unfortunately, the knowledge about antibiotic prophylaxis in RC is limited and mainly arises from retrospective cohort studies. Therefore, the European Association of Urology (EAU) guidelines on urological infections state no clear recommendation for periprocedural antibiotic prophylaxis in RC [6,7]. The most comprehensive randomized controlled trial (RCT) in this topic was recently published in 2024 and concluded: The findings of this RCT demonstrate noninferiority of 24-hour perioperative prophylaxis versus extended-duration of prophylaxis in preventing surgical side infections within 90 days after RC with urinary diversion and may contribute to antibiotic stewardship efforts (AMS) in urology [8]. However, one main limitation of this RCT is that different kinds of urinary diversion were included, e. g. orthotopic ileal neobladders (IN) with the highest risk of infectious complications and hospital readmission in comparison to ileal conduits. Logically, patients undergoing RC with IN are a special patient cohort with the highest risk for urological infections, but the data situation, especially in terms of homogeneous patient cohorts, is even worse.
Furthermore, there is a second important aspect in terms of infectious considerations in this special cohort: the management of asymptomatic bacteriuria (ASB). INs are associated with a high incidence of ASB especially during the first year after surgery. To best of our knowledge, there is only one prospective study about this issue available at the moment. Herein, the authors reported: There was spontaneous clearance of bacteriuria with time, with no antimicrobial manipulation. Soon after surgery there was a significant association between bacteriuria and nocturnal enuresis. The effect of antimicrobials on patients with nocturnal enuresis should be evaluated. Additionally, there is no clear definition of ASB in this special patient cohort available at the moment [8,9]. However, due the rising antimicrobial resistance rates, which are a global health concern, the management of ASB is of special interest. Therefore, ASB should be studied intensively even in special patient groups [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28].
To address this evidence-to-practice gap, we propose a Delphi consensus study [29] to identify the best antibiotic management and define procedural, patient-related and microbiological risk factors that warrant antibiotic intensified use in patients with RC and IN.
Objectives
The primary objective of this Delphi consensus study is to establish expert consensus on evidence-informed principles for antibiotic management in patients undergoing RC with IN, including (1) perioperative antibiotic prophylaxis, (2) antibiotic prophylaxis at catheter removal and (3) the definition, screening and treatment of ASB. The secondary objective is to identify procedural, patient-related and microbiological factors that may justify deviation from standard antibiotic management.
Study Design
We will employ a modified Delphi method consisting of three sequential and anonymous rounds. The study will adhere to the DELPHISTAR (Delphi studies in social and health sciences – recommendations for an interdisciplinary standardized reporting) guideline to ensure transparency, methodological rigor and reproducibility [29]. The full protocol will be made publicly available before commencement of the study. Initial Delphi items will be generated from a structured review of the available literature, current international guidelines and findings from the preceding multi-center survey of antibiotic practices in RC with IN. The draft item set will undergo review by the protocol committee for clarity, redundancy, and clinical relevance before Round 1.
Expert Panel
We aim to recruit approximately 30 - 40 experts in the fields of:
- Urology, experienced in urological infections and/or surgical experience in RC with IN
- Infectious Diseases and Antimicrobial Stewardship
- Microbiology
- Medical Oncologist, experienced in uro-oncology esp. bladder cancer
Participants will be selected based on:
- Peer-reviewed publications
- Involvement in guideline panels
- Recognized clinical or academic leadership
Experts will be drawn from across Europe, Latin America and North America to ensure global representation. In total approx. 30 - 40 Experts will be invited to participate in the Delphi consensus. They will be contacted by email and two reminders will be sent as needed.
Anonymity and Data Collection
All rounds will be conducted online using a secure survey platform managed by an external provider. Responses will be anonymized to prevent dominance bias and to allow candid input.
Round 1
Participants will receive a structured survey with background information on current evidence regarding the specific topic.
Each item will be rated on a 6-point Likert scale, where:
- 1–2 = Low or negligible importance
- 3–4 = Intermediate importance
- 5–6 = High importance
There will be open-text fields allowing participants to suggest additional comments or risk factors not listed or mentioned in the first round.
Round 2
Participants will receive anonymized summary statistics from Round 1 (median, IQR, distribution etc.). All original and newly suggested items will be re-rated, with the opportunity to revise scores based on group trends. Newly suggested items from round 1 will be presented.
Round 3
Only items that did not reach a consensus in Round 2 will be presented. Participants will again rate each item on the 6-point scale, aiming to resolve disagreement.
Consensus definition
Consensus in: ≥70% rate 5–6 and <15% rate 1–2
Consensus out: ≥70% rate 1–2 and <15% rate 5–6
No consensus: anything else
Dissemination
The final consensus statement will be submitted for publication peer-reviewed in high-impact journals.
Timeline
Month 1: Panel recruitment and final item generation
Months 2–3: Round 1
Months 3–4: Round 2
Months 4–5: Round 3
Months 5–6: Analysis and manuscript preparation
Delphi Questionnaire
Basic characteristics
1. What is your medical specialty?
o Urology
o Infectious Diseases and Antimicrobial Stewardship
o Microbiology
o Medical Oncologist
2. Where is your practice located?
o University Medical Center
o Urban Hospital
o Rural Hospital
o Private Practice
3. Approximately how many radical cystectomies (RC) with ileal neobladder (IN) reconstruction are performed on patients at your center each year?
o < 5
o 5 – 10
o 10 – 20
o > 20
4. How is RC typically performed at your center?
o open
o conventional-laparoscopic
o robot-assisted
5. How is IN surgery typically performed at your center?
o open
o conventional-laparoscopic
o robot-assisted
6. In your opinion, how should the RC part be performed surgically?
o open
o conventional-laparoscopic
o robot-assisted
o depending on institutional resources
o comments:
7. In your opinion, how should the IN part be performed surgically?
o open
o conventional-laparoscopic
o robot-assisted
o depending on institutional resources
o comments:
Periprocedural antibiotic prophylaxis
8. Is a single shot (or intra-operative repetition according to the half-life of antibiotic drug) enough as periprocedural empiric antibiotic prophylaxis for RC with IN?
o yes
o no
o not sure
o comments:
9. Is there are a different approach regarding periprocedural prophylaxis needed between open surgery or minimally-invasive surgery?
o yes
o no
o not sure
o comments:
10. This periprocedural empiric antibiotic prophylaxis should be used (best answer):
o Ampicillin/Sulbactam
o Piperacillin/Tazobactam
o Cefuroxime
o Ampicillin/Sulbactam plus metronidazole
o Cefuroxime plus metronidazole
o Ceftriaxone plus metronidazole
o Other:
11.Please, list factors for extending antibiotic usage after surgery?
o open, answer:
Antibiotic prophylaxis for catheter removal
12. Should antibiotic prophylaxis be used for removal of ureter catheters?
o yes
o no
o not sure
o comments, answer:
13. If yes, depending on which factors:
o open:
14. If yes, which antibiotic drug shall be used:
o Ampicillin/Sulbactam
o Piperacillin/Tazobactam
o Cefuroxime
o Ampicillin/Sulbactam plus metronidazole
o Cefuroxime plus metronidazole
o Ceftriaxone plus metronidazole
o according to urine culture
o Other:
15. Should antibiotic prophylaxis be used for removal of transurethral or suprapubic catheters?
o yes
o no
o not sure
o comments:
16. If yes, depending on which factors:
o open:
17. If yes, which antibiotic drug shall be used:
o Ampicillin/Sulbactam
o Piperacillin/Tazobactam
o Cefuroxime
o Ampicillin/Sulbactam plus metronidazole
o Cefuroxime plus metronidazole
o Ceftriaxone plus metronidazole
o according to urine culture
o Other:
Management of Asymptomatic Bacteriuria
Definition of asymptomatic bacteriuria in radical cystectomy with orthotopic ileal neobladder
18. How should ASB be defined in patients with RC and IN?
o ≥10⁵ CFU/mL in two consecutive samples for women and in a single sample for men from a midstream urine sample
o ≥10⁴ CFU/mL in two consecutive samples for women and in a single sample for men from a midstream urine sample
o Leukocyturia without a cut-off
o Leukocyturia with a cut-off of > 500 per ml
o Leukocyturia with a cut-off of, answer:
o Detection of microorganisms regardless of pathogen count
o Other:
19. What are risk factors for having ASB for those patients (all that apply):
o within 1 year after surgery
o female gender
o open surgery
o diabetes mellitus (well controlled)
o diabetes mellitus (not controlled)
o concomitant fungal infections
o urine leakage
o residual urine
o Other:
20. ASB has an impact on quality of life in those patients?
o yes
o no
o not sure
o comments:
21. What are risk factors for having clinical, relevant infection for those patients (all that apply):
o within 1 year after surgery
o female gender
o open surgery
o diabetes mellitus (well controlled)
o diabetes mellitus (not controlled)
o concomitant fungal infections
o urine leakage
o residual urine
o Other:
Screening of asymptomatic bacteriuria in radical cystectomy with orthotopic ileal neobladder
22. Should there be a regular screening for ASB for all patients with RC and IN?
o yes
o no
o not sure
o only in present of risk factors, please specify:
o comments:
23. How should be screened (of screening must be done) for ASB in those patients?
o Spontaneous Urine
o Catheterization of the neobladder
o Urine in a bag (freshly collected)
o other:
Treatment of asymptomatic bacteriuria in radical cystectomy with orthotopic ileal neobladder
24. Should ASB be treated with antibiotics regularly in patients with RC and IN?
o yes
o no
o not sure
o only in present of risk factors, please specify:
o comments:
Risk factors and special patient groups
25. Open surgical approach is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
26. Female gender is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
27. Diabetes mellitus (well controlled) is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
28. Diabetes mellitus (not controlled) is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
29. Concomitant fungal infections are a factor, which justifies intensified antibiotic usage plus antimycotic therapy in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
30. The use of ERAS (Enhanced recovery after surgery) is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
31. The gut microbiota is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
32. Previous multidrug-resistant organism is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
33. Recent antibiotic exposure is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
34. Impaired renal function (at CKD III) is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
35. Urinary leakage is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
36. Significant post-void residual (>100 ml) is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
37. Upper urinary tract obstruction is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
38. Upper urinary tract reflux is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
39. Urolithiasis is a factor, which justifies intensified antibiotic usage in RC with IN?
o negligible importance
o low importance
o low to intermediate importance
o intermediate importance
o high importance
o very importance
40. Should collateral damage of antibiotic usage in those patients coercively be reported?
o yes
o no
o not sure
o comments, answer:
Comments
o open, answer:
Funding
The study has no external funding and will only be supported by institutional infrastructure.
Ethics
The study involves healthcare professionals as expert participants and does not involve patients or collection of patient-level data. As such, ethic approval is not required under applicable guidelines.
Data Management and Analysis
All data will be processed anonymously. Summary statistics (medians, IQRs, consensus proportions etc.) will be used for analysis. Answers will be stratified according to registered variables such as medical specialty, throughout the domains to provide a comprehensive reporting of all studied aspects related to best practice and antibiotic management in RC with IN. Free-text data will be coded thematically.
References
- Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol. 2021, 79, 82–104. [Google Scholar] [CrossRef] [PubMed]
- Holzbeierlein, J.M.; Bixler, B.R.; Buckley, D.I.; Chang, S.S.; Holmes, R.; James, A.C.; et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J. Urol. 2024, 211, 533–8. [Google Scholar] [CrossRef] [PubMed]
- Zeuschner, P.; Linxweiler, J.; Mohr, R.; van Heemskerk, S.; Wagenpfeil, G.; Wagenpfeil, S.; et al. Robot-assisted versus open radical cystectomy: A cohort study on perioperative outcomes accounting for stage selection bias and surgical experience. Int. J. Med. Robot. Comput. Assist. Surg. 2021, 17, e2258. [Google Scholar] [CrossRef] [PubMed]
- Hayn, M.H.; Hellenthal, N.J.; Seixas-Mikelus, S.A.; Mansour, A.M.; Stegemann, A.; Hussain, A.; et al. Is patient outcome compromised during the initial experience with robot-assisted radical cystectomy? Results of 164 consecutive cases. BJU Int. 2011, 108, 882–7. [Google Scholar] [CrossRef] [PubMed]
- Lee, T.; MacDonald, L.; Lawen, T.; Kamat, A.M. Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what's new in 2025? Expert Rev. Anticancer Ther. 2025, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Rich, J.M.; Garden, E.B.; Arroyave, J.S.; Elkun, Y.; Ranti, D.; Pfail, J.L.; et al. Infections After Adoption of Antibiogram-directed Prophylaxis and Intracorporeal Urinary Diversion for Robot-assisted Radical Cystectomy. Eur. Urol. Focus 2024, 10, 612–9. [Google Scholar] [CrossRef] [PubMed]
- European Association of Urology guidelines 2026 on urological infections. Available online: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2026_2026-05-18-101552_yupb.pdf (accessed on 21 August 2026).
- Thurnheer, M.C.; Schürmann, A.; Huber, M.; Marschall, J.; Wuethrich, P.Y.; Burkhard, F.C. Perioperative Antibiotic Prophylaxis Duration in Patients Undergoing Cystectomy With Urinary Diversion. JAMA Netw. Open 2024, 7, e2439382. [Google Scholar] [CrossRef] [PubMed]
- Vejlgaard, M.; Maibom, S.L.; Joensen, U.L.; Moser, C.; Roder, A. Microbial Trends in Infection-related Readmissions Following Radical Cystectomy for Bladder Cancer. Urology 2024, 183, 134–40. [Google Scholar] [CrossRef] [PubMed]
- Abdel-Latif, M.; Mosbah, A.; El Bahnasawy, M.S.; Elsawy, E.; Shaaban, A.A. Asymptomatic bacteriuria in men with orthotopic ileal neobladders: possible relationship to nocturnal enuresis. BJU Int. 2005, 96, 391–6. [Google Scholar] [CrossRef] [PubMed]
- Burns, K.E.; Duffett, M.; Kho, M.E.; et al. A guide for the design and conduct of self-administered surveys of clinicians. Can. Med. Assoc. J. 2008, 179, 245–52. [Google Scholar] [CrossRef] [PubMed]
- Eysenbach, G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J. Med. Internet Res. 2008, 6, e34. [Google Scholar]
- Boparai, J.K.; Singh, S.; Kathuria, P. How to Design and Validate A Questionnaire: A Guide. Curr. Clin. Pharmacol. 2018, 13, 210–5. [Google Scholar] [CrossRef] [PubMed]
- Dell’Oglio, P.; Mazzone, E.; Lambert, E.; Vollemaere, J.; Goossens, M.; Larcher, A.; et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery. Eur. Urol. Focus 2021, 7, 352–8. [Google Scholar] [CrossRef] [PubMed]
- Richards, K.A.; Kader, K.; Pettus, J.A.; Smith, J.J.; Hemal, A.K. Does initial learning curve compromise outcomes for robot-assisted radical cystectomy? A critical evaluation of the first 60 cases while establishing a robotics program. J. Endourol. 2011, 25, 1553–8. [Google Scholar] [CrossRef] [PubMed]
- Posada Calderon, L.; Al Hussein Al Awamlh, B.; Shoag, J.; Patel, N.; Nicolas, J.D.; Scherr, D.S. The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy. Urol. Oncol. Semin. Orig. Investig. 2021, 39, 6–12. [Google Scholar] [CrossRef] [PubMed]
- Rai, B.P.; Bondad, J.; Vasdev, N.; Adshead, J.; Lane, T.; Ahmed, K.; et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst. Rev. 2019, 4, CD011903. [Google Scholar] [CrossRef] [PubMed]
- Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol. 2021, 79, 82–104. [Google Scholar] [CrossRef] [PubMed]
- Holzbeierlein, J.M.; Bixler, B.R.; Buckley, D.I.; Chang, S.S.; Holmes, R.; James, A.C.; et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J. Urol. 2024, 211, 533–8. [Google Scholar] [CrossRef] [PubMed]
- Berkut, M.V.; Belyaev, A.M.; Galunova, T.Y.; Tyapkin, N.I.; Reva, S.A.; Nosov, A.K. Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial. Bladder Cancer 2024, 10, 221–32. [Google Scholar] [CrossRef] [PubMed]
- Kitano, H.; Watanabe, E.; Tadera, K.; Nakano, Y.; Tasaka, S.; Yukihiro, K.; et al. Urine culture–guided antibiotic prophylaxis reduces febrile pyelonephritis after ureteral stent removal following radical cystectomy. World J. Urol. 2026, 44, 249. [Google Scholar] [CrossRef] [PubMed]
- Hussein, A.A.; Mahmood, A.W.; Ahmad, A.; Houenstein, H.; Harrington, G.; Khan, M.; et al. Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections After Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial. J. Urol. 2025, 214, 147–55. [Google Scholar] [CrossRef] [PubMed]
- Skupin, P.A.; Pena, V.N.; Jacobs, B.L. 24-HourPerioperative Antibiotic Prophylaxis for Cystectomy and Urinary Diversions—Less Is More. Jama Netw. Open 2024, 7, e2439361. [Google Scholar] [CrossRef] [PubMed]
- Wullt, B.; Holst, E.; Steven, K.; Carstensen, J.; Pedersen, J.; Gustaffson, E.; et al. Microbial Flora in Ileal and Colonic Neobladders. Eur. Urol. 2004, 45, 233–9. [Google Scholar] [CrossRef] [PubMed]
- Wullt, B.; Bergsten, G.; Carstensen, J.; Gustafsson, E.; Gebratsedik, N.; Holst, E.; et al. Mucosal Host Responses to Bacteriuria in Colonic and Ileal Neobladders. Eur. Urol. 2006, 50, 1065–72. [Google Scholar] [CrossRef] [PubMed]
- Suriano, F.; Gallucci, M.; Flammia, G.P.; Musco, S.; Alcini, A.; Imbalzano, G.; et al. Bacteriuria in patients with an orthotopic ileal neobladder: urinary tract infection or asymptomatic bacteriuria? BJU Int. 2007, 101, 1576–9. [Google Scholar] [CrossRef] [PubMed]
- Scherrer, M.; Brunaiova, L.; Furrer, M.; John, H.; Schwartz, J.; Lucca, I.; et al. How safe is teaching radical cystectomy?: Results from the prospective Swiss society of urology database. World J. Urol. 2026, 44, 133. [Google Scholar] [PubMed]
- Diamond, I.R.; Grant, R.C.; Feldman, B.M.; Pencharz, P.B.; Ling, S.C.; Moore, A.M.; et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J. Clin. Epidemiol. 2014, 67, 401e409. [Google Scholar] [CrossRef] [PubMed]
- Niederberger, M.; Schifano, J.; Deckert, S.; Hirt, J.; Homberg, A.; Köberich, S.; et al. Delphi studies in social and health sciences-Recommendations for an interdisciplinary standardized reporting (DELPHISTAR) - Results of a Delphi study. PLoS ONE 2024, 19, e0304651. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.